VIVEVE MEDICAL INC (VIVE)
US92852W5013 - Common Stock
VIVE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 195 industry peers in the Health Care Equipment & Supplies industry. While VIVE seems to be doing ok healthwise, there are quite some concerns on its profitability. VIVE is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
VIVE had negative earnings in the past year.
VIVE had a negative operating cash flow in the past year.
VIVE had negative earnings in each of the past 5 years.
In the past 5 years VIVE always reported negative operating cash flow.
1.2 Ratios
VIVE has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
VIVE has a Gross Margin of 16.39%. This is in the lower half of the industry: VIVE underperforms 78.34% of its industry peers.
VIVE's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for VIVE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 16.39% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-37.5%
GM growth 5Y-22.91%
2. Health
2.1 Basic Checks
VIVE does not have a ROIC to compare to the WACC, probably because it is not profitable.
VIVE has more shares outstanding than it did 1 year ago.
The debt/assets ratio for VIVE has been reduced compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of -34.95, we must say that VIVE is in the distress zone and has some risk of bankruptcy.
VIVE has a worse Altman-Z score (-34.95) than 94.47% of its industry peers.
VIVE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -34.95 |
ROIC/WACCN/A
WACC8.03%
2.3 Liquidity
A Current Ratio of 0.89 indicates that VIVE may have some problems paying its short term obligations.
VIVE has a worse Current ratio (0.89) than 94.47% of its industry peers.
VIVE has a Quick Ratio of 0.89. This is a bad value and indicates that VIVE is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.74, VIVE is not doing good in the industry: 88.94% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.74 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 32.74% over the past year.
Looking at the last year, VIVE shows a small growth in Revenue. The Revenue has grown by 2.34% in the last year.
Measured over the past years, VIVE shows a decrease in Revenue. The Revenue has been decreasing by -2.09% on average per year.
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q11.94%
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y-2.09%
Revenue growth Q2Q4.21%
3.2 Future
Based on estimates for the next years, VIVE will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.12% on average per year.
The Revenue is expected to grow by 50.55% on average over the next years. This is a very strong growth
EPS Next Y7.44%
EPS Next 2Y19.13%
EPS Next 3Y18.12%
EPS Next 5YN/A
Revenue Next Year7.41%
Revenue Next 2Y31.78%
Revenue Next 3Y50.55%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for VIVE. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VIVE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as VIVE's earnings are expected to grow with 18.12% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.13%
EPS Next 3Y18.12%
5. Dividend
5.1 Amount
VIVE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
VIVEVE MEDICAL INC
NASDAQ:VIVE (1/18/2023, 7:00:02 PM)
After market: 0.2151 0 (-2.27%)0.2201
-0.04 (-15.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.36M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 16.39% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.56
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.89 | ||
| Quick Ratio | 0.74 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)32.74%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y7.44%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)2.34%
Revenue growth 3Y-29.73%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y